share_log

HC Wainwright & Co. Maintains Buy on Kezar Life Sciences, Raises Price Target to $20

Benzinga ·  Sep 25, 2023 06:17

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Kezar Life Sciences (NASDAQ:KZR) with a Buy and raises the price target from $18 to $20.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment